MORE THAN JUST PATIENT’S
European association taking the interests of European pALS
EupALS is an European association taking the interests of European pALS (ALS patients) to heart. We thus want to create equal rights for all the European pALS and provide better access to research and information about it.
Subscribe to our newsletter
NEWS
-
EMA announcement positive CHMP opinion for Biogen Tofersen (Qualsody)
23 February 2024 New treatment for rare motor neurone disease recommended for approval EMA has recommended granting a marketing authorisation in the European Union for a new therapy for the… More >>
-
EUpALS in Lancet Neurology editorial November 2023
Speeding up research to improve the lives of people with ALS Advances in research over the past few years have provided a greater understanding of the pathophysiology, genetics, and risk… More >>
MISSION
Aiming to unite all the European ALS associations…
… to fight harder together on a European scale
Stand up for the rights of all the European pALS
Create awareness on a European scale
Improve access to & information about research
Create the same rules for ALS research across Europe
ALS RESEARCH NEWS
Checkout the most recent Articles And Insights on ALS Research
-
VectorY Therapeutics Receives U.K. MHRA Authorization and EMA Approval to Initiate Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People Living with Amyotrophic Lateral Sclerosis (ALS)
April 28, 2026 The authorizations represent an expansion of the PIONEER-ALS clinical trial,currently enrolling participants at clinical trial sites in the U.S. VectorY Therapeutics, a leader in vectorized antibody therapies… More >>
-
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
April 30, 2026 87 percent reduction in risk of death compared to patients who received placebo (hazard ratio: 0.13, p-value: < 0.0001) Corcept Therapeutics, a commercial-stage company engaged in the… More >>
-
Novartis ASTRALS trial with VHB937 in ALS fully enrolled
Community Statement:Enrollment complete for Novartis Phase 2 (ASTRALS) Clinical Trial in amyotrophic lateral sclerosis (ALS) More >>
-
Community Update:First Participant Enrolled in the PREVAiLS Phase 3 ALS Study
March 30, 2026 Dear ALS community, We are delighted to share that a new global, pivotal Phase 3 clinical trial, called PREVAiLS, studying the investigational drug pridopidine, has enrolled its… More >>